Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03974997 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis

Study acronym: TWEAK
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 1, 2020 to Jun 16, 2027 · Start date changed from estimate of Sep 1, 2019 to Jun 16, 2023 · Completion date: Sep 1, 2021 to Jun 16, 2027 · 5 morev2 Show 8 more changesShow less
    • Primary completion date: Sep 1, 2020 to Jun 16, 2027
    • Start date changed from estimate of Sep 1, 2019 to Jun 16, 2023
    • Completion date: Sep 1, 2021 to Jun 16, 2027
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints expanded, about 18 words
    • Site details revised
    • Study title expanded, about 9 words
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.
Trial Details
NCT Number NCT03974997
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Multiple Sclerosis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov